Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin. A 52-week, Randomised, Double-blind, Placebo-controlled Trial (PIONEER 8 - Insulin add-on)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 13 Dec 2017
At a glance
- Drugs Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms PIONEER 8
- Sponsors Novo Nordisk
- 21 Nov 2017 According to a Novo Nordisk media release, the trial is expected to be completed in 2018.
- 25 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 06 Feb 2017 Status changed from not yet recruiting to recruiting.